Orange County Register

Agendia, a cancer diagnostics company with headquarters in Huntington Beach and Amsterdam, has received $23 million in equity investment.

The proceeds will be used to speed up the commercialization in U.S. markets of MammaPrint, is U.S. Food and Drug Administration approved test using gene assessment profiling. It is highly accurate in identifying patients who are likely to have a cancer recurrance within five years following surgery.

Half the money came from an undisclosed family investment firm. Two independent entrepreneurs invested $1 million each, and the rest of the money came from existing investors.

“We are excited to be a part of Agendia’s continued growth and to enable the company to bolster its strategic marketing and sales efforts as it brings MammaPrint to an ever increasing number of breast cancer patients,” said Gertjan van der Baan, a board member representing van Herk Group, Agendia’s largest investor.

Agendia collaborates with pharmaceutical companies to develop highly effective personalized cancer drugs. The company’s tests help physicians more accurately tailor cancer treatments.

Other investing stories….

• O.C. venture capitalist: proposed law could damage industry
• O.C. home electronics firm sells off Swiss unit
• Local investors seek to jumpstart new O.C. ventures
• O.C. company gets second buyout bid of $360 million
• O.C. company buys software firm
• Some big-money startups close their doors
• O.C. company is sold for $400 million
• O.C. animation firm sold
• O.C. drug company receives $4 million
• O.C. chipmaker gets $4 million in N.Y. deal
• Local company pays $14.5 million for fuel technology
• Balboa Bay Racquet Club has new owner
• Q2 investment in O.C. firms plunges 65%

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.